



Updated Monthly

July 13, 2022

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:




Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

July 13, 2022

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

Aging	2	Medical Countermeasures.....	23
Air Force Office of Scientific Research	3	Mental Health	24
Army Applications Lab.....	3	Multiple Sclerosis	24
Army Research Laboratory	3	National Science Foundation	25
Army Research Office	4	National Virtual Biotechnology Laboratory	25
Artificial Intelligence & Machine Learning.....	4	Neurofibromatosis.....	25
BARDA.....	4	Office of Naval Research	25
Biodefense	5	Parkinson's Disease.....	26
Biointelligence and Biosecurity.....	5	Patient-Centered Research	26
Biospecimen Science.....	5	Precision Medicine	28
Burn Injury	6	Public Health	29
Cancer	6	Rare Diseases	29
Cannabis Research.....	11	Reconstructive Transplant	30
Cardiovascular and Pulmonary Health.....	11	Regenerative Medicine	30
Chronic Disease	13	Small Business Development.....	30
Cognitive and Brain Health	14	Social Determinants of Health.....	31
Combat Readiness Medical Research.....	16	Substance Use Disorder	31
Coronavirus	17	Synthetic Biology.....	33
DARPA.....	17	Toxicology.....	33
Defense Threat Reduction Agency.....	18	US Air Force Academy	33
Endocrine and Metabolic Diseases.....	18	US Army Combat Capabilities Development Command.....	34
Energy Science	19	US Army Research Institute	34
Global Health	19	US Military Academy.....	34
Health IT.....	19	US Navy	35
HIV/AIDS	20	USAMRDC Extramural BAA	35
Immunology & Infectious Disease.....	21	USSOCOM Extramural R&D	35
Lupus	22	Vision Health.....	36
Maternal and Pediatric Health	22	Warfighter Medical Optimization Division	36



July 15, 2022 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EDT (FREE and open to all) then from 10:30-11am EDT (premium service and private consultation for G2G and GBG customers). Click [here](#) to register.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (4)		
1.	Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) (NIH/NIA) PAR-22-213	This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. https://grants.nih.gov/grants/guide/pa-files/PAR-22-213.html	Dependent on proposal, for up to 5 years	Letter of intent: 12/25/22 Proposal: 1/25/23
2.	NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44/R41/R42 Clinical Trial Optional) (NIH/NIA) RFA-AG-23-029 (R43/R44) RFA-AG-23-030 (R41/R42)	The goal of these FOAs is to foster the career development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-029.html (R43/R44) https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-030.html (R41/R42)	Up to \$275,766, for up to 2 years (Phase I) Up to \$1,838,436, for up to 3 years (Phase II)	Letter of intent: 1/17/23 Proposal: 2/17/23
3.	Pre-Announcement: Healthy Aging: Optimizing Physical and Mental Functioning Across the Aging Continuum -- Cycle 3 2022 (PCORI)	The Healthy Aging Targeted PCORI Funding Announcement will solicit applications for CER studies that focus on different phases of the aging continuum and aim to achieve one or more of the following four goals: maintaining function and independence; facilitating chronic disease management; supporting individuals with significant functional impairment; reducing caregiving burden and improving quality of life. https://www.pcori.org/funding-opportunities/announcement/healthy-aging-optimizing-physical-and-mental-functioning-across-aging-continuum-cycle-3-2022	Up to \$5 million, for up to 5 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE OFFICE OF SCIENTIFIC RESEARCH (2)		
4.	Air Force Office of Scientific Research Broad Agency Announcement (DoD/Air Force) FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. https://www.grants.gov/web/grants/view-opportunity.html?oppld=305996	Dependent upon proposal	Proposals accepted on a rolling basis
5.	Research Interests of the Air Force Office of Scientific Research (DoD/Air Force) FA9550-21-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Engineering and Complex Systems team leads the discovery and development of the fundamental and integrated science that advances future air and space flight. The Information and Networks Team is organized to support many U.S. Air Force and Space Force priority areas including autonomy, space situational awareness, and cyber security. The Physical Sciences Team leads the discovery and transition of foundational physical science to enable air, space, and cyber power. The Chemistry and Biological Sciences Team is responsible for research activities in fundamental chemistry, biology, mechanics, and biophysics research. https://www.grants.gov/web/grants/view-opportunity.html?oppld=334084	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
		ARMY APPLICATIONS LAB (1)		
6.	Army Applications Lab BAA for Disruptive Applications (DoD/Army) W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppld=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
		ARMY RESEARCH LABORATORY (1)		
7.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD/Army) W911NF-17-S-0003-11	The ARL BAA seeks proposals for research based on the following S&T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies. https://www.grants.gov/web/grants/view-opportunity.html?oppld=292896	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY RESEARCH OFFICE (2)		
8.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD/Army) W911NF-17-S-0002-07	ARL's strategy is based on eleven Foundational Research Competencies: Biological and Biotechnology Sciences; Electromagnetic Spectrum Sciences; Energy Sciences; Humans in Complex Systems; Mechanical Sciences; Military Information Sciences; Network, Cyber and Computational Sciences; Photonics, Electronics, and Quantum Sciences; Sciences of Extreme Materials; Terminal Effects; and Weapons Sciences. These competencies are structured to create discovery, innovation, and transition of technologies for Army transformational overmatch. https://www.grants.gov/web/grants/view-opportunity.html?oppId=292877	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22
9.	Army Research Office Broad Agency Announcement Staff Research Program (DoD/Army) W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (1)		
10.	Dynamics, Control and Systems Diagnostics (NSF) PD-22-7569	The DCSD program promotes the fundamental science and engineering of dynamic systems to advance solutions to urgent societal problems, such as mitigating the impacts of climate change; responding to epidemics, cyber-attacks, extreme weather, and other natural and man-made events; promoting efficient and equitable production and distribution of resources; developing resilient infrastructure; improving the experience of work and learning; and meeting the challenges of aging and illness. https://beta.nsf.gov/funding/opportunities/dynamics-control-and-systems-diagnostics-dcsd-o	Dependent upon proposal	Proposals accepted on a rolling basis
		BARDA (2)		
11.	BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA) BAA-20-100-SOL-00002	BARDA is currently accepting submissions through the EZ-BAA: AOI #2: Infection Severity and Solving Sepsis; AOI #5: ReDirect; AOI #8: Bringing Laboratory Testing to the Home.; AOI #9: Digital Health Tools for Pandemic Preparedness.; AOI #10: Next Generation Sequencing based Agnostic Diagnostic for Respiratory RNA Virus Pathogens; AOI #11a: Home-based, OTC Diagnostics for the Detection of SARS-CoV-2; AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection; AOI #12: Mitigating Long-term Effects of Respiratory Distress; AOI #13: Endotyping for Host-Directed Therapeutics https://sam.gov/opp/of026c861ae84ef499be99d7604ef3db/view https://drive.hhs.gov/partner.html	Up to \$750,000, per award	Proposals accepted on a rolling basis until 2/3/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA		
12.	BARDA Broad Agency Announcement (HHS/BARDA) BARDABAA	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics. https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view https://www.medicalcountermeasures.gov/barda/barda-baa	Dependent upon proposal	White papers: 12/15/22
		BIODEFENSE (1)		
13.	Dear Colleague Letter: Sentinel Systems that Detect, Recognize, Actuate, and Mitigate Emergent Biological Threats (DREAM Sentinels) (NSF) NSF 22-077	Proposals should include biosensing and bioactuation elements that address a biological threat. The biosensing element should leverage the power of modern biotechnology and deliver robust and specific recognition of the biological threat. The results of bioactuation should alert the user, destroy the threat, protect the host, or initiate an immune response or other strategies that would mitigate the threat. https://beta.nsf.gov/funding/opportunities/sentinel-systems-detect-recognize-actuate-and-mitigate-emergent-biological	Dependent upon proposal and award mechanism	Proposals accepted on a rolling basis
		BIOINTELLIGENCE AND BIOSECURITY (1)		
14.	Biointelligence and Biosecurity for the Intelligence Community (B24IC) Seedling Research Topic (DoD/Navy) N66001-22-S-4704	IARPA seeks novel research ideas from multidisciplinary teams pursuing advanced research topics capable of supporting Biointelligence and Biosecurity. https://sam.gov/opp/5e18674979114ae5a1de02459b7af2a7/view	Up to \$4 million, for up to 2 years	White paper: 7/25/22 Proposal: 9/13/22
		BIOSPECIMEN SCIENCE (1)		
15.	Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-22-049	This FOA supports extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as "liquid biopsies", or other biospecimens as described in this FOA. http://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html	Up to \$250,000 per year, for up to 5 years	Letter of intent: 8/13/22 Proposal: 9/13/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BURN INJURY (1)		
16.	Burn Digital Assessment (MTEC) MTEC-22-08-BDA	The overall goal of this RPP is to develop a hand-held, rugged device capable of providing an objective measure of burn severity by calculating burn size (in terms of TBSA) and burn depth, including the proportion of TBSA for the various burn depths. The minimum acceptable technology readiness level (TRL) at the time of submission of the White Paper is at least TRL 5. https://www.mtec-sc.org/wp-content/uploads/2022/06/MTEC-22-08-BDA-RPP-Final.pdf	Up to \$4.8 million, for up to 2 years	White paper: 7/14/22
		CANCER (68)		
17.	Applied regulatory science research to understand factors that affect the safety and treatment response of underrepresented subgroups in oncology therapeutic development (HHS/FDA) FOR-FD-23-009	OCE is interested to understand factors that affect the safety and treatment response in oncology therapeutic development for demographic subgroups that have been historically underrepresented in oncology trials. FDA seeks to obtain information about these special populations to assess whether evidence generated in clinical trials to support the safety and effectiveness of therapeutics is generalizable to the larger patient population. https://www.grants.gov/web/grants/view-opportunity.html?oppld=341847	TBD	TBD
18.	Pre-Announcement: Novel approaches to support therapeutic development in ultra-rare cancers (HHS/FDA) FOR-FD-23-010	OCE is interested in supporting therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. https://www.grants.gov/web/grants/view-opportunity.html?oppld=341846	TBD	TBD
19.	NOSI: Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy (NIH) NOT-CA-22-063	This NOSI, with 15 linked grants, aims to promote mechanistic research aimed at better understanding the pathophysiology of irAEs. It is anticipated that the mechanistic research supported through this NOSI will build the foundational knowledge which will ultimately lead to better strategies to predict, prevent and/or ameliorate toxicities that can arise as a consequence of current immunotherapeutic regimens, and improve treatment outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-063.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/5/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
20.	NOSI: Technologies and Informatics Tools for Cancer Metabolomics (NIH/NCI) NOT-CA-22-083	This announcement seeks to address the need for new technologies designed explicitly to overcome technical challenges and advance cancer metabolomics. Research could include launching new and innovative analytical and software platforms, improving the ability of researchers to process more complex samples, and/or developing novel computational approaches or tools that facilitate metabolomics data analysis, interpretation, and integration. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-083.html	Dependent upon proposal and award mechanism 5/6/2022	Multiple deadlines; NOSI open through 12/31/24
21.	NOSI: Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer (NIH/NCI) NOT-CA-22-085	This NOSI, with 16 linked grants, aims to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-085.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/27
22.	Pre-Announcement: NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) (NIH/NCI) NOT-CA-22-094	This FOA supports areas of cancer research relevant to the mission of the DCTD, DCP, and CRCHD. These include but are not limited to: preclinical and clinical studies that focus on the development and testing of anti-cancer, symptom management, and cancer prevention interventions, including combinations of agents; diagnostic and treatment methodologies; validation of predictive biomarkers for clinical use; clinical and translational studies that seek to reduce the unequal burden of cancer in our society via research of underserved populations; testing of new models that closely parallel the development and progression of human cancers or the development of disease and treatment-related morbidities; comparative oncology studies of prevention, symptom management, and/or treatment of pet dogs with spontaneous cancers. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-094.html	Up to \$275,000, for up to 2 years	Estimated post date: 8/12/22 Estimated proposal date: 10/20/22
23.	Pre-Announcement: Mechanistic links between diet, lipid metabolism, and tumor growth and progression (R01/R21 Clinical Trial Not Allowed) (NIH/NCI) NOT-CA-22-106 (R01) NOT-CA-22-107 (R21)	These FOAs have three goals: one, to support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; two, bridge the historically divided fields of nutrition and molecular metabolism; and three, stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-106.html (R01) https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-107.html (R21)	Up to \$500,000 per year, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Estimated post date: 8/10/22 Estimated proposal date: 10/10/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
24.	Pre-Announcement: The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) (NIH/NCI) NOT-CA-22-112	This FOA will solicit applications that apply systems-level approaches to tackle questions in metastasis that will integrate with and complement ongoing research in the Metastasis Research Network (MetNet). https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-112.html	Up to \$500,000 per year	Estimated post date: 8/31/22 Estimated proposal date: 11/7/22
25.	Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-22-161	This FOA will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations with substantial community engagement. https://grants.nih.gov/grants/guide/pa-files/PAR-22-161.html	Dependent upon proposal, for up to 5 years	Proposal: 7/29/22
26.	Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-22-162	NCI encourages grant applications to support research in established cancer epidemiology cohort studies. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum. https://grants.nih.gov/grants/guide/pa-files/PAR-22-162.html	Dependent upon proposal, for up to 5 years	Proposal: 7/29/22
27.	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01/R21 Clinical Trial Optional) (NIH/NCI) PAR-22-164 (R01) PAR-22-165 (R21)	These FOAs support meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. https://grants.nih.gov/grants/guide/pa-files/PAR-22-164.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html (R21)	Up to \$500,000 per year, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R21)



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
28.	<p>Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01/R21 Clinical Trial Optional) (NIH/NCI)</p> <p>PAR-22-198 (R01) PAR-22-199 (R21)</p>	<p>The goal of the PAIRS program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. These FOAs solicit research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy.</p> <p>https://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html (R21)</p>	<p>Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)</p>	<p>Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R21)</p>
29.	<p>FY22 Breast Cancer Breakthrough Award Levels 1 and 2 (BTA12-2) Breakthrough Award Level 3 (BTA3-2) Breakthrough Award Level 4 (BTA4-2) Era of Hope Scholar Award (EOHS-2) Innovator Award (INNOV-2) Transformative Breast Cancer Consortium Award (TBCCA-2) (DoD/CDMRP)</p> <p>W81XWH-22-BCRP-BTA12-2 W81XWH-22-BCRP-BTA3-2 W81XWH-22-BCRP-BTA4-2 W81XWH-22-BCRP-EOHS-2 W81XWH-22-BCRP-INNOV-2 W81XWH-22-BCRP-TBCCA-2</p>	<p>Considering the current breast cancer landscape and the BCRP's mission to end breast cancer, the BCRP seeks applications that address the following overarching challenges:</p> <ul style="list-style-type: none"> • Prevent breast cancer (primary prevention) • Identify determinants of breast cancer initiation, risk, or susceptibility • Distinguish deadly from non-deadly breast cancers • Conquer the problems of overdiagnosis and overtreatment • Identify what drives breast cancer growth; determine how to stop it • Identify why some breast cancers become metastatic • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival • Eliminate the mortality associated with metastatic breast cancer <p>https://cdmrp.army.mil/funding/bcrp</p>	<p>Up to \$25 million, for up to 4 years Dependent upon award mechanism</p>	<p>Pre-Application: 8/3/22 Invited proposal: 11/2/22 (BTA3-2/ BTA4-2/ INNOV-2/ TBCCA-2) Pre-Application: 9/22/22 Proposal: 10/6/22 (BTA12-2/ EOHS-2)</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
30.	FY22 Kidney Cancer Academy of Kidney Cancer Investigators – Early-Career Scholar Award (AKCIECSA) Clinical Trial Award (CTA) Nurse-Initiated Research Award (NIRA) (DoD/CDMRP) W81XWH-22-KCRP-AKCIECSA W81XWH-22-KCRP-CTA W81XWH-22-KCRP-NIRA	Applications submitted to the FY22 KCRP should address one or more of the following Focus Areas: <ul style="list-style-type: none"> • Conduct basic biology research on kidney cancer. • Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death. • Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers. • Develop novel therapeutic strategies for the treatment of kidney cancer. • Identify and implement strategies to improve quality of life and survivorship. • Identify and implement strategies to mitigate health disparities. • Support preparation and development of the next generation of kidney cancer researchers, or cultivate collaborations in kidney cancer research or patient care. https://cdmrp.army.mil/funding/kcrp	Up to \$2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/29/22 Proposal: 10/20/22
31.	FY22 Melanoma Research Program (MRP) Focused Program Award- Rare Melanomas (FPA) Melanoma Academy Scholar Award (MASA) Mid-Career Accelerator Award (MCAA) Team Science Award (TSA) (DoD/CDMRP) W81XWH-22-MRP-FPA W81XWH-22-MRP-MASA W81XWH-22-MRP-MCAA W81XWH-22-MRP-TSA	Applications submitted to the FY22 MRP must address one or more of the following Focus Areas: <ul style="list-style-type: none"> • Investigate topics relevant to rare melanomas that cover the entire research spectrum. • Identify and understand risk factor determinants for melanoma. • Develop prediction and surveillance tools • Understand how precursor lesions and environmental/endogenous factors influence melanomagenesis. • Develop new tools for the detection and diagnosis of melanoma, which includes easily accessible technology for physicians and dermatologists. • Identify how the tumor microenvironment impacts tumor initiation, response to therapy, progression, recurrence, and/or dormancy. • Delineate the molecular pathways that influence metastatic spread, recurrence, and/or dormancy. https://cdmrp.army.mil/funding/mrp	Up to \$2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/14/22 Application: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
32.	FY22 Prostate Cancer Data Science Award (DSA); Health Disparity Research Award (HRDA); Translational Science Award (TSA) (DoD/CDMRP) W81XWH-22-PCRP-DSA W81XWH-22-PCRP-HDRA W81XWH-22-PCRP-TSA	Applications to the FY22 PCRP are required to address one or more of the following FY22 PCRP Overarching Challenges: <ul style="list-style-type: none"> • Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer • Develop treatments that improve outcomes for men with lethal prostate cancer • Advance health equity and reduce disparities in prostate cancer • Define the biology of prostate cancer progression to lethal prostate cancer to reduce death https://cdmrp.army.mil/funding/pcrp	Up to \$1 million, for up to 3 years Dependent upon award mechanism	Pre-application: 8/4/22 Proposal: 8/25/22
33.	FY22 Rare Cancers, Concept Award (CA) (DoD/CDMRP) W81XWH-22-RCRP-CA	CA applications submitted to the FY22 RCRP must address one or more of the following Focus Areas: <ul style="list-style-type: none"> • Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment. • Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness. • Therapy: Identify novel therapeutic strategies, including drug repurposing. https://cdmrp.army.mil/funding/rcrp	Up to \$100,000, for up to 1 year	Pre-Application: 7/18/22 Proposal: 8/29/22
		CANNABIS RESEARCH (1)		
34.	Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional) (NIH/NIDA) RFA-DA-23-011	NIDA seeks applications to develop and maintain a medicinal cannabis use registry to assess the medical conditions reported as reasons for using medicinal cannabis, how and what products are being used, and the associated medical outcomes. The goal of this registry is to inform research, policy, and clinical recommendation practices on medicinal cannabis, associated conditions, and outcomes. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-011.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 10/15/22 Proposal: 11/15/22
		CARDIOVASCULAR AND PULMONARY HEALTH (23)		
35.	NOSI: Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) (NIH/NHLBI) NOT-HL-22-030	This NOSI promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. It is expected that projects supported by this NOSI will utilize ex vivo preparations or 3-D multi-cellular in vitro systems of human lung cells and will employ state-of-art multi-omics measures to better understand specific pathobiological processes in systems of interacting cell types. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-22-030.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
36.	NOSI: Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities (NIH) NOT-OD-22-154	This NOSI focuses specifically on preventive interventions addressing cardiometabolic risk factors across the lifespan in populations that experience health disparities. Efforts to improve these risk factors should be based on research that identifies and addresses relevant determinants of health at individual, interpersonal, organizational, community, and societal levels. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-154.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25
37.	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) (NIH/NHLBI) PAR-22-189	This FOA supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. https://grants.nih.gov/grants/guide/pa-files/PAR-22-189.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/11/22 Proposal: 10/11/22
38.	Clinical and Data Coordinating Centers for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3/U24 Clinical Trial Required) (NIH/NHLBI) PAR-22-192 (UG3/UH3) PAR-22-193 (U24)	These FOAs support applications to develop and implement a Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials. Clinical trials supported by this FOA include Phase II and above clinical trials that will enroll participants from two or more recruitment sites. https://grants.nih.gov/grants/guide/pa-files/PAR-22-192.html (UG3/UH3) https://grants.nih.gov/grants/guide/pa-files/PAR-22-193.html (U24)	Dependent upon proposal, for up to 5 years	Letter of intent: 9/11/22 Proposal: 10/11/22
39.	Pre-Announcement: Improving Health Outcome for Patients with Inflammatory Bowel Disease (CDC/ERA) RFA-DP-23-002	The purposes of this FOA are to 1) conduct epidemiological studies; 2) design and pilot activities to enhance IBD management; 3) design and pilot education and outreach activities; and 4) identify health disparities in IBD management and outcomes and tailor evidence-based interventions to reduce these disparities. https://www.grants.gov/web/grants/view-opportunity.html?oppld=341189	Up to \$800,000	Estimated post date: 11/2/22 Estimated proposal date: 1/16/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC DISEASE (2)		
40.	Pre-Announcement: Telehealth to Optimize Management of Multiple Chronic Conditions among Vulnerable Populations in Primary Care -- Cycle 3 2022 (PCORI)	This FOA is soliciting applications that respond to the following question: What is the comparative clinical effectiveness of different approaches to incorporating access to and use of telehealth to optimize management of multiple chronic conditions in primary care? Applications should focus on community-dwelling individuals with multiple chronic conditions and should be powered to allow for conclusions regarding one or more vulnerable populations of interest. https://www.pcori.org/funding-opportunities/announcement/telehealth-optimize-management-multiple-chronic-conditions-among-vulnerable-populations-primary-care-cycle-3-2022	Up to \$10 million, for up to 5 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
		CHRONIC PAIN (3)		
41.	Pre-Announcement: HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required) (NIH) NOT-NR-22-015	This FOA will support applications for UG3/UH3 phased cooperative research to accelerate implementation of effective, non-opioid interventions for chronic pain management in rural and remote populations. Interventions addressing acute pain in rural and remote populations may also be responsive. https://grants.nih.gov/grants/guide/notice-files/NOT-NR-22-015.html	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$1 million per year, for up to 3 years (UH3)	Estimated post date: 8/15/22 Estimated proposal date: 11/15/22
42.	HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01/U24 Clinical Trial Required/Optional) (NIH/NIDA/NICHD/NCCIH) RFA-DA-23-041 (R01) RFA-DA-23-042 (U24)	NIDA seeks studies for pharmacologic management with or without non-pharmacological approaches for managing chronic pain in those currently using long-term opioids, as well as applications for a single resource center to complement a broader HEAL program on reducing opioid-related harms and improving quality of life in patients on long-term opioid therapy (LTOT). https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-041.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-042.html (U24)	Up to \$750,000 per year, for up to 5 years (R01) \$1.5 million per year, for up to 5 years (U24)	Letter of intent: 8/27/22 Proposal: 9/27/22
43.	Pre-Announcement: Centers for Oceans and Human Health 4: Impacts of Climate Change on Oceans and Great Lakes (COHH4) (P01 Clinical Trial Optional) (NIH/NIEHS/NSF) NOT-ES-22-011	These multi-component projects will characterize and evaluate the impact of climate change on emerging public health threats associated with marine and Great Lakes Basin environments. Each center will include distinct but integrated research projects on marine or Great Lakes exposures, mechanisms of toxicity or human exposure, and the influence of climate change, using multidisciplinary ocean science, analytical, toxicological and biomedical approaches. https://grants.nih.gov/grants/guide/notice-files/NOT-ES-22-011.html	Up to \$950,000	Estimated post date: 8/19/22 Estimated proposal date: 11/1/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH (15)		
44.	NOSI: Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities (R43/R44) (NIH/NICHHD) NOT-HD-22-009	This notice invites small business applications specifically aimed at developing or building upon existing technological tools to improve assessments, interventions, and outcomes for children and individuals with intellectual, developmental and physical disabilities. Applications proposing tools and/or technologies may include: home monitors, point-of-care diagnostic technologies, mobile devices, mobile device apps, and wearable sensors and monitors. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-009.html	Up to \$275,766, for up to 2 years (Phase I) Up to \$1.8 million, for up to 3 years (Phase II)	Proposal: 9/5/22
45.	Pre-Announcement: BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed) (NIH) NOT-MH-22-265	This FOA will support the creation of Centers for accelerated engineering and optimization of high-impact, molecular technologies to monitor and/or manipulate brain cell activity in experimental animals. The Centers will produce high-impact molecular probes such as, but not limited to, fluorescent protein indicators of neuronal state variables, molecular integrators of neural activity, optogenetic, chemogenetic, sonogenetic, magnetogenetic actuators, and activity-dependent molecular switches. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-265.html	TBD	Estimated post date: 12/31/22 Estimated proposal date: 6/28/23
46.	Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-22-208	This FOA supports studies that characterize the structure of protein aggregates found in the Alzheimer's disease related dementias (ADRD) such as alpha-synuclein, Tau, TDP-43, TMEM106B, and FUS at a high, atomic-level resolution, using approaches such as cryo-electron microscopy (cryo-EM), cryo-electron tomography (cryo-ET), and nuclear magnetic resonance (NMR) spectroscopy. https://grants.nih.gov/grants/guide/pa-files/PAR-22-208.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/7/22 Proposal: 10/7/22
47.	Impact of the Microbiome-Gut-Brain Axis on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed) (NIH/NIA/NINDS) PAR-22-211	This FOA will support mechanistic research focused on a more rigorous in-depth examination of the potential interactions between the microbiome and genetic and non-genetic molecular targets that influence AD/ADRD. It is expected that these studies will address the clinical relevance of the microbiome on disease initiation, progression, or modification, and will lead ultimately to better therapeutic interventions. https://grants.nih.gov/grants/guide/pa-files/PAR-22-211.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 9/5/22 Proposal: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
48.	Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42/R43/R44 Clinical Trial Optional) (NIH/NIA/NINDS) PAS-22-196 (R41/R42) PAS-22-197 (R43/R44)	These FOAs encourage research on, and the commercialization of, novel therapies, devices, products, and healthcare programs and practices to prevent the onset of AD/ADRD, and to reduce the burden that AD/ADRD places on individuals, their families, and society at large. https://grants.nih.gov/grants/guide/pa-files/PAS-22-196.html (R41/R42) https://grants.nih.gov/grants/guide/pa-files/PAS-22-197.html (R43/R44)	Up to \$500,000, for up to 2 years (Phase I) Up to \$2.5 million, for up to 3 years (Phase II)	Proposal: 9/5/23
49.	Cognitive Neuroscience (CogNeuro) (NSF) PD 15-1699	The Cognitive Neuroscience Program seeks highly innovative proposals aimed at advancing a rigorous understanding of the neural mechanisms of human cognition. Central research topics for consideration by the program include attention, learning, memory, decision-making, language, social cognition, and emotions. https://beta.nsf.gov/funding/opportunities/cognitive-neuroscience-cogneuro	Dependent upon proposal, for up to 5 years	Proposal: 8/13/22 2/11/23
50.	Network for Personalization of Diagnostic Tests for Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) in Older Adults with Multiple Chronic Conditions (MCCs) (U24 Clinical Trial Optional) (NIH/NIA) RFA-AG-23-032	The national consortium will: 1) assemble existing data and acquire real-world data to ensure that the research sample is large with adequate representation of older adults living with well-characterized MCCs, and incorporate pre-specified subgroup analyses; 2) analyze data for performance and accuracy of biomarkers, including blood, cerebrospinal fluid (CSF), and imaging, in older patients living with MCCs; and 3) conduct pilot studies involving specific AD/ADRD imaging and/or biomarkers in persons living with MCCs. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-032.html	Up to \$1.15 million, for up to 5 years	Letter of intent: 9/17/22 Proposal: 10/17/22
51.	BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed) (NIH) RFA-EB-22-001	This FOA solicits applications for team-centric development and validation of non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using a UG3/UH3 phased grant mechanism. https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-001.html	Up to \$300,000 per year, for up to 3 years (UG3) Up to \$750,000 per year, for up to 4 years (UH3)	Letter of intent: 9/13/22 Proposal: 10/13/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
52.	BRAIN Initiative: Team-Research BRAIN Circuit Programs - TeamBCP (U19 Basic Experimental Studies with Humans Required/Clinical Trial Not Allowed) (NIH) RFA-NS-22-039 RFA-NS-22-040	Applications should focus on overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should aim to understand these circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-039.html https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-040.html	Dependent upon proposal, for up to 5 years	Letter of intent: 8/16/22 Proposal: 9/16/22
53.	BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 Basic Experimental Studies with Humans Required) (NIH) RFA-NS-22-041	This RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to the brain from invasive surgical procedures. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-041.html	Dependent upon proposal, for up to 5 years	Letter of intent: 8/23/22 Proposal: 9/23/22
54.	Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required) (NIH/NIA/NINDS) RFA-NS-23-001	This FOA solicits applications for pragmatic clinical trials to decrease or prevent negative clinical outcomes due to vascular contributions to cognitive impairment and dementia (VCID), including locally representative NIH defined populations that experience health disparities in dementia. Examples of responsive projects and interventions that affect VCID outcomes include, but are not limited to, blood pressure control implementation; lifestyle modification using aerobic exercise; and early detection and treatment of VCID risk factors. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-001.html	Dependent upon proposal, for up to 5 years	Letter of intent: 8/14/22 Proposal: 9/15/22
		COMBAT READINESS MEDICAL RESEARCH (1)		
55.	FY22 Combat Readiness Medical, Rapid Development and Translational Research Award (DoD/CDMRP) W81XWH-22-S-CRRP	The intent of the FY22 CRRP RDTRA is to support research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines. Research under this award mechanism should represent a rapid advancement or innovative “leap ahead” and have the potential for broadly applicable, cross-cutting advances. https://cdmrp.army.mil/funding/crrp	Up to \$3.2 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 6/23/22 Invited Application: 9/14/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CORONAVIRUS (3)		
56.	Pre-Announcement: Advancing COVID health disparities focused research to strengthen and advance health equity (HHS/FDA) FOR-FD-23-004	OMHHE is interested in research proposals that will contribute to advancing understanding of long COVID or post-COVID conditions for racial and ethnic minorities, or contribute to informing the continued evaluation of the safety and efficacy of FDA approved products (therapeutics, diagnostics, and vaccines) for the treatment, prevention, or diagnosis of COVID-19. These research proposals should support evaluation of outcomes by demographic data including, but not limited to, ethnicity, race, age, disability and geography. https://www.grants.gov/web/grants/view-opportunity.html?oppId=341830	TBD	TBD
57.	Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required/Optional) (NIH/NIMH) PAR-22-112 PAR-22-113	These FOAs aim to address urgent, time-sensitive mental health research questions related to COVID-19. Research supported will improve public health in the near term by informing responses to the current pandemic. All research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting health disparities. https://grants.nih.gov/grants/guide/pa-files/PAR-22-112.html https://grants.nih.gov/grants/guide/pa-files/PAR-22-113.html	Up to \$750,000 per year, for up to 3 years	Letter of intent: 7/25/22 Proposal: 8/25/22
		DARPA (3)		
58.	Biological Technologies BAA (DoD/DARPA) HR001122S0034	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biomedical, and Biodefense https://sam.gov/opp/dfeg3a5637fc419a8ea392ee949f9c79/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 4/20/23
59.	Redefining Possible - 2022 (DoD/DARPA) HR001122S0040	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. https://sam.gov/opp/a517e20d661b431aa933e55263a2bc42/view	Up to \$1 million, for up to 18 months	Proposals accepted on a rolling basis until 6/21/23
60.	Defense Sciences Office, Office-wide (DoD/DARPA) HR001122S0041	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Global Change. https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/14/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (2)		
61.	FY2022-2026 DTRA Chemical / Biological Technologies BAA (DoD/DTRA) HDTRA122S0002	DTRA is seeking optimum approaches to meet technology objectives within the areas listed below, with a goal to identify and select science and technology projects that can be transitioned to joint acquisition programs: Detection – Chemical and Biological; Digital Battlespace Management; Protection – Individual and Collective; Hazard Mitigation; Threat Agent Science; Vaccines; Medical Diagnostics; Therapeutics; Chemical Medical Countermeasures; Medical Futures; and Warfighter Integration. https://sam.gov/opp/ab3a036713364a2aa02c4187e5964449/view	Dependent upon proposal	Topic 1 Submissions: 8/16/22
62.	Research and Development Innovations Broad Agency Announcement (DoD/DTRA) HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across three interrelated thrust areas derived from the 2019 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): <ul style="list-style-type: none"> • Understand the environment, threats, and vulnerabilities • Control, defeat, disable, and dispose of threats • Safeguard the force and manage consequences https://sam.gov/opp/98f9fec4443f4e5d988d2680d85c97fo/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
		DUCHENNE MUSCULAR DYSTROPHY (2)		
63.	FY22 Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) Translational Research Award (TRA) (DoD/CDMRP) W81XWH-22-DMDRP-IDA W81XWH-22-DMDRP-TRA	Applications for the for the FY22 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that focus on primary pathology of DMD. Therapies that will be efficacious across the life span, particularly in adolescents and adults, are encouraged. Applications for the FY22 DMDRP Translational Research Award must address at least one of the following Focus Areas: Translational and clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve care and quality of life; Assessment of clinical trial tools and outcome measures; and Extension or expansion of existing preclinical translational data in support of a specific therapeutic development. https://cdmrp.army.mil/funding/dmdrp	Up to \$1.35 million, for up to 3 years Dependent on award mechanism	Pre-Application: 8/3/22 Invited proposal: 11/15/22
		ENDOCRINE AND METABOLIC DISEASES (1)		
64.	Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-22-021	This FOA invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved prevention of type 1 diabetes. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-021.html	Up to \$1 million per year, for up to 3 years	Letter of intent: 1/28/23 Proposal: 2/28/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENERGY SCIENCE (1)		
65.	FY 2022 Continuation of Solicitation for the Office of Science Financial Assistance Program (DoE) DE-FOA-0002562	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppld=335970	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/22
		GLOBAL HEALTH (1)		
66.	FY2022 Development Innovation Ventures (USAID) APS-7200AA22APS00001	DIV sources proposals for innovations that address international development challenges and improve the lives of people living in poverty in developing countries around the world. DIV partners with innovators to save lives, reduce poverty, strengthen democracies, respond to climate change, mitigate the consequences of COVID-19, help people emerge from humanitarian crises, and more. https://www.grants.gov/web/grants/view-opportunity.html?oppld=336301	Up to \$15 million, dependent on proposal and availability of funds	Proposals accepted on a rolling basis until 10/31/22
		HEALTH IT (5)		
67.	Research Infrastructure for Trauma with Medical Observations (RITMO) (DoD/DARPA) HR001122S0043	The Research Infrastructure for Trauma with Medical Observations (RITMO) program, will combine large-volume multi-modal sensor, intervention, and medical outcome data obtained from trauma patients during the early post-injury period into a single database. https://sam.gov/opp/c8d42ae0a28a4103a9ceb1d3eae57439/view	Dependent upon proposal and award mechanism	Abstract: 7/20/22 Proposal: 9/1/22
68.	Smart Noninvasive Assays of Physiology (SNAP) (DoD/DARPA) HR001122S0044	The SNAP program aims to develop a portable, fieldable, noninvasive device to assess warfighter physiological states, focusing on those associated with physical and cognitive readiness. Importantly, the device will leverage a combination of multi-omic, multiplexed biomarker detection, as well as integrated assessment and readout, to predict human performance in the context of real-world, DoD-relevant tasks. https://sam.gov/opp/274893a663d44c84970c698d234da1e7/view	Dependent upon proposal and award mechanism	Abstract: 8/11/22 Proposal: 9/15/22
69.	Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences (DMS/NIGMS) (NIH/NSF) NSF 22-600	This FOA supports fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. https://www.nsf.gov/pubs/2022/nsf22600/nsf22600.htm	Up to \$1.2 million, for up to 3 years Dependent upon award mechanism	Proposal: 9/19/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT		
70.	More Monitoring of Cognitive Change, Continued (M3C3) (U2C Clinical Trial Optional) (NIH/NIA) RFA-AG-23-021	This FOA invites applications to expand the content, design, and implementation of research infrastructure collectively known as the Mobile Toolbox (MTB) Project, by addressing the need to (1) add assessments on mobile devices of non-cognitive socioemotional psychological functions, health states, and contextual factors that may modify cognitive performance; and (2) enable widespread dissemination and support for use of the tools developed for monitoring of age, state, context, or health condition-related changes in cognitive and non-cognitive abilities on mobile devices. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-021.html	Up to \$4.8 million per year, for up to 5 years	Letter of intent: 9/20/22 Proposal: 10/20/22
71.	Harnessing Technologies to Support Oral Health Promotion and Management Outside the Dental Setting (UG3/UH3 Clinical Trial Required) (NIH/NIDCR) RFA-DE-23-009	This FOA encourages research that develops and/or adapts and tests technology-facilitated behavioral, social, and organizational tools for use in oral health promotion and management outside the dental setting. Of particular interest are tools that harness mobile, web, sensor, or other technology-based platforms with the potential to improve oral care at home or in the community; to facilitate needs assessment, treatment planning, and engagement; and to expand access to quality care for those who are under-served. https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-23-009.html	Up to \$200,000 per year, for up to 2 years (UG3) Up to \$300,000 per year, for up to 5 years (UH3)	Letter of intent: 10/10/22 Proposal: 11/10/22
		HIV/AIDS (4)		
72.	Pre-Announcement: Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) (NIH/NIDA) NOT-DA-22-070	The upcoming FOA will solicit applications for research on mechanisms of inflammasome activation and its link to immune functions in people with HIV and substance use disorders. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-22-070.html	TBD	Estimated post date: 11/16/22 Estimated proposal date: 3/1/23
73.	Molecular Dynamics of HIV (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-050	This FOA supports computational dynamic modeling of molecular complexes regulating the HIV life cycle, immune responses, and therapeutic interventions in HIV/AIDS using existing and new HIV and HIV/host cell structural datasets. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-050.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 11/7/22 Proposal: 12/7/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
74.	Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies (R01/R21 Clinical Trial Not Allowed) (NIH/NIMH/NINDS) RFA-MH-22-280 (R01) RFA-MH-22-281 (R21)	This FOA supports studies on the epigenetic mechanisms regulating HIV CNS latency and/or neuropathogenesis using in-vitro, ex-vivo, and in-vivo systems. Strategies to target epigenetic pathways for achieving sustained HIV remission and treatment of HIV associated-CNS dysfunction are encouraged. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-280.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-281.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 11/2/22 Proposal: 12/5/22
		IMMUNOLOGY & INFECTIOUS DISEASE (8)		
75.	Armed Forces Pest Management Board (DoD/AFPMB) AFPMB-BAA-22-01	The AFPMB is soliciting pre-proposals for original and innovative research designed to develop new interventions for protection of deployed military personnel from diseases caused by arthropod-borne pathogens and to improve control of bed bugs and filth flies. Diseases of significant concern include Lyme disease, malaria, dengue fever and other arboviruses. https://sam.gov/opp/4fa92ea106a84436bce4c20cb6627e23/view	Up to \$900,000	White papers accepted on a rolling basis until 10/30/24
76.	National Priorities: Research on Disinfectants, Disinfection By-Products (DBPs), and Opportunistic Pathogens in Drinking Water Distribution Systems (EPA) EPA-G2022-ORD-H1	More information is needed on the occurrence of DBPs and opportunistic pathogens, along with identifying environmental conditions and niches favorable to colonization, microbial growth, and propagation in drinking water distribution systems. This RFA solicits innovative research to address knowledge gaps on the occurrence of pathogens and DBPs in drinking water distribution systems across the USA. https://www.grants.gov/web/grants/view-opportunity.html?oppId=341462	Up to \$2.123 million; 25% cost matching required	Proposal: 8/31/22
77.	NOSI: Achieving Tissue Robustness Through Harnessing Immune System Plasticity (NIH/NIDCR) NOT-DE-22-005	NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-22-005.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
78.	Understanding the Clinical History of Bacterial Sexually Transmitted Infections (STI) to Accelerate Diagnostic and Vaccine Development (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-034	This FOA aims to support studies on the clinical history of three sexually transmitted infections (STIs): syphilis, gonorrhea, and chlamydia. Improved understanding of the human immune response after infection through diagnosis and treatment will provide a much-needed knowledge base to accelerate vaccine and diagnostic development. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-034.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 8/12/22 Proposal: 9/12/22
79.	Partnerships for Development of Vaccines Against Select Enteric Pathogens (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-037	This FOA aims to solicit research applications for projects focused on advancing development of vaccine candidates against Enterotoxigenic <i>Escherichia coli</i> (ETEC), <i>Salmonella enterica</i> serotype Paratyphi A, and two <i>Shigella</i> species, <i>Shigella flexneri</i> and <i>Shigella sonnei</i> . https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-037.html	Up to \$750,000 per year, for up to 5 years	Letter of intent: 8/14/22 Proposal: 9/14/22
		LUPUS (3)		
80.	FY22 Lupus Idea Award (IA) Impact Award (IPA) Transformative Vision Award (TVA) (DoD/CDMRP) W81XWH-22-LRP-TVA W81XWH-22-LRP-IPA W81XWH-22-LRP-IA	The FY22 Lupus Research Program includes three award mechanisms: The Idea Award, the Impact Award, and the Transformative Vision Award. Applications must address one or more of the Focus Areas listed here , appropriate to the award sought. https://cdmrp.army.mil/funding/lrp	Up to \$2.5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/16/22 Proposal: 9/1/22
		MATERNAL AND PEDIATRIC HEALTH (18)		
81.	NOSI: Research to Support Regulatory Science on Infant Formula (NIH) NOT-HD-22-016	This NOSI invites investigator-initiated applications addressing major research gaps in the evidence base to support regulation of biologically active substances, components and molecules that are intended for use in infant formula. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-016.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH		
82.	NOSI: Advancing Research on Early Pregnancy Loss (NIH/NICHD/ORWH) NOT-HD-22-026	While approximately half of all cases of EPL appear to be due to embryonic aneuploidy, very little is known about the physiologic and pathophysiologic processes that underlie non-aneuploid EPL. This NOSI seeks to address these critical knowledge gaps by encouraging basic, translational and clinical studies on biological processes that may uncover potential etiologies of EPL and RPL. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-026.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25
83.	Pre-Announcement: Open Competition: Environmental influences on Child Health Outcomes (ECHO) Pregnancy Cohort Study Sites. Clinical Trial Not Allowed (UG3/UH3) (NIH/NIMH/NCCIH) NOT-OD-22-171	This FOA will invite applications for new ECHO Cohort Study Sites to extend and expand the capacity of the ECHO Cohort to further investigate the roles of a broad range of early exposures from society to biology, including the preconception period, on ECHO's five key child health outcome areas—pre-, peri- and postnatal, upper and lower airways, obesity, neurodevelopment, and positive health—among diverse populations. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-171.html	TBD	Estimated post date: 8/1/22 Estimated proposal date: 11/21/22
		MEDICAL COUNTERMEASURES (3)		
84.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB (DoD/Army) CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
85.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) (DoD/DTRA) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES		
86.	CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed) (NIH) PAR-22-209	This FOA solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. https://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html	Up to \$350,000 per year, for up to 3 years (UG3) Up to \$450,000 per year, for up to 3 years (UH3)	Letter of intent: 9/17/22 Proposal: 10/17/22
		MENTAL HEALTH (2)		
87.	Novel assays to Address Translational Gaps and Building in vivo Preclinical Assays of Circuit Engagement (UG3/UH3/R01 Clinical Trial Optional/Not Allowed) (NIH/NIMH) PAR-22-169 (UG3/UH3) PAR-22-170 (R01)	These FOAs support neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development, and in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. https://grants.nih.gov/grants/guide/pa-files/PAR-22-169.html (UG3/UH3) https://grants.nih.gov/grants/guide/pa-files/PAR-22-169.html (R01)	Dependent on proposal, for up to 5 years (UG3/UH3) Up to \$250,000 per year, for up to 5 years (R01)	Letter of intent: 9/21/22 Proposal: 10/21/22 (UG3/UH3) Letter of intent: 9/5/22 Proposal: 10/5/22 (R01)
		MULTIPLE SCLEROSIS (1)		
88.	FY22 Multiple Sclerosis, Early Investigator Research Award (EIRA) (DoD/CDMRP) W81XWH-22-MSRP-EIRA	All applications submitted to the FY22 MSRP EIRA program must address one or more of the following Focus Areas: Central Nervous System Regenerative Potential in Demyelinating Conditions; Correlates of Disease Activity and Progression in MS; Biology and Measurement of MS Symptoms; Factors Contributing to or Associated with MS Etiology, Prodrome, Onset, and Disease Course. https://cdmrp.army.mil/funding/pa/W81XWH-22-MSRP-EIRA-GG.pdf	Up to \$320,000, for up to 3 years	Pre-Application: 8/2/22 Proposal: 10/3/22 (EIRA)



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION (1)		
89.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) (NSF) NSF 22-551	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. Click here for project pitch details and for the full list of topics click here . https://beta.nsf.gov/funding/opportunities/small-business-innovation-research-program-phase-i-sbirsttr-phase-i	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/1/22 to 10/26/22
		NATIONAL VIRTUAL BIOTECHNOLOGY LABORATORY (1)		
90.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	NVBL is a consortium of National laboratories, taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. https://science.osti.gov/nvbl	Dependent upon solicitation and proposal	N/A
		NEUROFIBROMATOSIS (1)		
91.	Biology and Therapeutic Development for Cutaneous Neurofibromas (NTAP)	This RFA supports therapeutics for the peripheral nerve tumors that afflict people with Neurofibromatosis Type 1 (NF1). http://www.n-tap.org/nf1-and-cutaneous-neurofibroma/	Up to \$1 million, for up to 3 years	Letter of intent: 8/5/22 Proposal: 9/2/22
		OFFICE OF NAVAL RESEARCH (1)		
92.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology (DoD/Navy) N00014-22-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PARKINSON'S DISEASE (4)		
93.	Extracellular RNA Sequencing Research Resource for the Accelerating Medicines Partnership® Parkinson's Disease (AMP®PD) (R24 - Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-23-014	This FOA seeks applicants experienced in the isolation and sequencing of RNA from brain-derived extracellular vesicles to develop a research resource for the Accelerating Medicines Partnership in Parkinson's Disease (AMP PD). https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-014.html	Dependent on proposal, for up to 1 year	Proposal: 9/19/22
94.	FY22 Parkinson's Research Program (PRP) Early Investigator Research Award (EIRA); Investigator-Initiated Research Award (IIRA); Synergistic Idea Award (SIA) (DoD/CDMRP) W81XWH-22-PRP-EIRA W81XWH-22-PRP-IIRA W81XWH-22-PRP-SIA	Applications submitted to the FY22 PRP must address one or more of the following Focus Areas: <ul style="list-style-type: none"> • Biological mechanisms and biomarkers of non-motor symptoms that could lead to the development of treatments for PD. Non-motor symptoms of interest include: Cognitive, Psychiatric, Sleep, Autonomic, and Sensory dysfunctions; Fatigue. • Biological mechanisms and biomarkers of non-pharmacological interventions for non-motor symptoms in PD. https://cdmrp.army.mil/funding/prp	Up to \$3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/16/22 Proposal: 9/1/22
		PATIENT-CENTERED RESEARCH (10)		
95.	Broad Pragmatic Studies Funding Announcement -- 2022 Standing PFA (PCORI)	This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research; and Improving Healthcare Systems. Special Areas of Emphasis include: Addressing Racism, Discrimination, and Bias in Healthcare Systems and Care Delivery; Aspirin to Prevent Preeclampsia; Caregiver-Delivered Interventions for Intellectual and Developmental Disabilities; Optimizing Prevention and Treatment of Postpartum Hemorrhage. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2022-standing-pfa	Up to \$10 million, for up to 5 years Dependent upon award mechanism	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
96.	Improving Methods for Conducting Patient-Centered Outcomes Research -- 2022 Standing PFA (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-outcomes-research-2022-standing-pfa	Up to \$750,000, for up to 3 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
97.	Pre-Announcement: Engagement Award: Building Capacity for Small Organizations to Engage in PCOR/CER -- October 2022 Cycle (PCORI)	The Engagement Award: Building Capacity for Small Organizations to Engage in PCOR/CER funding opportunity will support two-year projects that help small organizations and their communities build capacity and skills to take part in the PCOR/CER process. https://www.pcori.org/funding-opportunities/announcement/engagement-award-building-capacity-small-organizations-engage-pcorcer-october-2022-cycle	Up to \$250,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/24/23
98.	Pre-Announcement: Engagement Award: Capacity Building -- October 2022 Cycle (PCORI)	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-october-2022-cycle	Up to \$250,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/11/23
99.	Pre-Announcement: Engagement Award: Dissemination Initiative -- October 2022 Cycle (PCORI)	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-october-2022-cycle	Up to \$250,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/11/23
100.	Pre-Announcement: Engagement Award: Stakeholder Convening Support -- October 2022 Cycle (PCORI)	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-october-2022-cycle	Up to \$100,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/11/23
101.	Pre-Announcement: Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 3 2022 (PCORI)	This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance, so that these interventions are effectively and sustainably integrated into practice. https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-cycle-3-2022	Up to \$1.5 million, for up to 3 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
102.	Pre-Announcement: Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 3 2022 (PCORI)	For the Cycle 3 2022 PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-competition-pfa-implementation-findings-pcoris-research-investments-cycle-3-2022	Up to \$2.5 million, for up to 3 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
103.	Pre-Announcement: Phased Large Awards for Comparative Effectiveness Research -- Cycle 3 2022 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-cycle-3-2022	TBD	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
104.	Science of Engagement PCORI Funding Announcement (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity in engagement and research; How engagement supports successful research, thereby advancing PCORI's National Priorities for Health. https://www.pcori.org/funding-opportunities/announcement/science-engagement-pcori-funding-announcement	Up to \$1.5 million, for up to 3 years Dependent upon award mechanism	Letter of intent: 8/9/22 Proposal: 11/15/22
		PRECISION MEDICINE (2)		
105.	Enhancing Therapeutic Gene Expression in Human Gene Therapy (FNIH) 2022-BGTC003	This RFP solicits proposals that will advance our understanding of how AAV transduces tissues and cells of clinical importance and/or develop approaches to significantly improve transduction efficiencies in such tissues and cells. https://fnih.org/sites/default/files/2022-06/BGTC%20RFP%20AAV%20Biology%20Gene%20Expression%20REVISED%20RFP%20FINAL.pdf	Up to \$250,000 per year, for up to two years	Proposal: 8/28/22
106.	Enhancing AAV Vector Production for Human Gene Therapy (FNIH) 2022-BGTC004	This RFP solicits proposals that will advance our understanding of and/or improve the production of high-quality and high-titer recombinant AAV (rAAV) vectors for gene therapy in humans. https://fnih.org/sites/default/files/2022-06/BGTC%20RFP%20AAV%20Biology%20Vector%20Production%20REVISED%20RFP%20FINAL.pdf	Up to \$250,000 per year, for up to two years	Proposal: 8/28/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PUBLIC HEALTH (2)		
107.	Pre-Announcement: Advancing Policy as a Public Health Intervention to Reduce Morbidity, Mortality and Disparities in HIV, Viral Hepatitis, STDs, and Tuberculosis (CDC/NCHHSTP) CDC-RFA-PS23-2309	This FOA aims to strengthen the ability of leaders who make decisions in public health to identify and implement science-based policy interventions that will save lives, save money, reduce health disparities, and protect adults and youth from HIV, viral hepatitis, STDs, and TB. To accomplish this, the applicant(s) will apply legal epidemiology and policy analysis principles to determine where and how laws, policies, and regulations are applied and conduct analyses to evaluate the effect of law and policy on health and economic outcomes. https://www.grants.gov/web/grants/view-opportunity.html?oppId=341540	TBD	Estimated post date: 10/31/22 Estimated proposal date: 12/30/22
108.	HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Optional) (NIH) RFA-DA-23-045	This RFA aims to accelerate understanding of emerging drug threats as they develop and thereby improve harm reduction efforts. It is anticipated that applicants to this RFA will propose to develop assessment technologies to improve assessment of emerging drug threat prevalence in multiple environments. These include including emergency departments, rehabilitation treatment clinics, forensic analytical labs and even to provide harm reduction tools to users at the point of drug consumption. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-045.html	Dependent on proposal, for up to 5 years	Letter of intent: 1/2/23 Proposal: 2/2/23
		RARE DISEASES (2)		
109.	Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required (FDA/OOPD) RFA-FD-23-001	This FOA will fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html	Up to \$650,000 per year, for up to 4 years	Letter of intent: 9/26/22 Proposal: 10/25/22
110.	Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) (NIH/NCATS/NIMH) RFA-TR-22-030	This FOA is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins associated with rare disease. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-030.html	Up to \$100,000 for one year	Letter of intent: 9/17/22 Proposal: 10/17/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RECONSTRUCTIVE TRANSPLANT (3)		
111.	FY22 Reconstructive Transplant Advanced Technology Development Award (ATDA) Concept Award (CA) Investigator- Initiated Research Award (IIRA) (DoD/CDMRP) W81XWH-22-RTRP-ATDA W81XWH-22-RTRP-CA W81XWH-22-RTRP-IIRA	The FY22 RTRP supports research of exceptional scientific merit to refine approaches for and increase access to reconstructive transplants and state-of-the-art immunotherapy. Applications must address one or more of the Focus Areas appropriate to each award. https://cdmrp.army.mil/pubs/press/2022/22trppreann https://cdmrp.army.mil/funding/rtrp	Up to \$1.5 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 7/27/22 Invited Application: 10/19/22 (ATDA/IIRA) Pre-Application: 9/28/22 Application: 10/19/22 (CA)
		REGENERATIVE MEDICINE (3)		
112.	Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials, Studies, and Planning Grant (UG3/UH3 – Clinical Trial Required/Not Allowed) (NIH) RFA-HL-23-017 (UG3/UH3) RFA-HL-23-019 (U01) RFA-HL-23-020 (R34)	The RMIP aims to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. These FOAs support applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies, contribute an enhanced understanding of stem cell product attributes, and promote data sharing. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-017.html (UG3/UH3) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-019.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-020.html (R34)	Up to \$345,000 per year, for up to 5 years (UG3/UH3) Up to \$250,000 per year, for up to 2 years (U01) Up to \$150,000 per year, for up to 2 years (R34) 1:1 cost matching required	Letter of intent: 9/2/22 Proposal: 10/6/22
		SMALL BUSINESS DEVELOPMENT (6)		
113.	DoD SBIR/STTP 22.4 (DoD) DoD SBIR 2022.4	The objectives of the DoD SBIR Program include stimulating technological innovation, strengthening the role of small business in meeting DoD research and development needs, fostering and encouraging participation by minority and disadvantaged persons in technological innovation, and increasing the commercial application of DoD-supported research or research and development results. https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/	Dependent upon proposal and award mechanism	Dependent upon program



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
114.	PHS 2022-2 Omnibus Solicitation of the NIH/CDC/FDA for (Parent SBIR/STTP [R43/R44/R41/R42] Clinical Trials Vary) (NIH/CDC/FDA) PA-22-176 PA-22-177 PA-22-178 PA-22-179	US small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) identified in these FOAs are encouraged to submit SBIR/STTP grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). https://seed.nih.gov/sites/default/files/HHS_Program_Descriptions.pdf https://grants.nih.gov/grants/guide/pa-files/PA-22-176.html https://grants.nih.gov/grants/guide/pa-files/PA-22-177.html https://grants.nih.gov/grants/guide/pa-files/PA-22-178.html https://grants.nih.gov/grants/guide/pa-files/PA-22-179.html	Up to \$275,766, for up to 2 years (Phase I) Up to \$1.8 million, for up to 3 years (Phase II)	Proposal: 9/5/22
115.	Pre-Announcement: DOE SBIR/STTP (DoE)	Topics of the DOE SBIR/STTP are anticipated to include: Bioimaging, AI/ML, and bioenergy. https://science.osti.gov/-/media/sbir/pdf/TechnicalTopics/FY23-Phase-I-Release-1-Combined-Topics07082022.pdf	Up to \$1.6 million Dependent upon proposal and award mechanism	Post date: 8/8/22 Proposal: 10/11/22
		SOCIAL DETERMINANTS OF HEALTH (23)		
116.	NOSI: Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity (NIH) NOT-OD-22-135	This NOSI encourages research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes. It is therefore an opportunity for future research to advance nutrition equity, including: Research to understand the mechanisms and pathways between food insecurity and neighborhood food environments on wellbeing and health and various health outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-135.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/29/24
		SUBSTANCE USE DISORDER (15)		
117.	NOSI: High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior (NIH/NIDA) NOT-DA-22-058	Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD, and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-induced neuroinflammation. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-22-058.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
118.	NOSI: High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior (NIH/NIDA) NOT-DA-23-004	Research areas of general interest include but are not limited to: human and animal genetic studies of vulnerability to addiction, molecular genetics and genomic studies related to the response to addictive drugs, epigenetic mechanisms of substance use disorders and addiction, cell biology studies of addiction, development of neural pathways and brain structures that mediate SUDs and addiction and bioinformatic approaches to better model the genetics of SUDs, including data integration, methods development, and machine learning. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-23-004.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25
119.	NIDA Program Project Grant Applications (Po1 Clinical Trial Optional) (NIH/NIDA) PAR-22-201	NIDA seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, health services, HIV/AIDS and co-occurring opportunistic infections and associated consequences in substance abusing populations, medication development, or other research areas relevant to drug abuse. https://grants.nih.gov/grants/guide/pa-files/PAR-22-201.html	Dependent on proposal, for up to 5 years	Letter of intent: 8/25/22 Proposal: 9/25/22
120.	Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed) (NIH/NIDA) RFA-DA-23-017	This FOA supports the development of psychoplastogenic compounds and new in vivo psychedelic behavioral pharmacology models for drug discovery and drug development for treating Substance Use Disorders (SUD), excluding alcohol use disorder. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-017.html	Up to \$320,000, for up to 1 year (Phase I) Up to \$2.5 million, for up to 3 years(Phase II)	Letter of intent: 10/14/22 Proposal: 11/18/22
121.	Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42/R43/R44 Clinical Trial Optional) (NIH/NIDA) RFA-DA-23-019 (R41/R42) RFA-DA-23-020 (R43/R44)	DDTs and MDDTs developed with funds from this FOA are expected to support investigators and medical product developers by facilitating and expediting regulatory approval of new medical products developed for diagnosis, monitoring, and/or treatment of patients with SUD. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-019.html (R41/R42) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-020.html (R43/R44)	Up to \$320,000, for up to 1 year (Phase I) Up to \$2.5 million, for up to 3 years (Phase II)	Letter of intent: 10/14/22 Proposal: 11/14/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
122.	Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) (NIH) RFA-TR-22-011	This FOA aims to support early-stage research to increase our knowledge of understudied proteins of the druggable proteome and enable the scientific community to identify and validate new targets for pain, opioid use disorder (OUD), and/or overdose (OD). These awards will support generation of preliminary data and tools around eligible understudied protein(s) identified by the HEAL Program with the intent of elucidating the function of these proteins in the context of pain, OUD and/or OD and obtaining sufficient preliminary data and/or research resources for subsequent R01 applications and/or drug discovery/development projects. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-011.html	Up to \$275,000, for up to 2 years	Letter of intent: 8/7/22 Proposal: 8/22/22
		SYNTHETIC BIOLOGY (1)		
123.	Building Synthetic Microbial Communities for Biology, Mitigating Climate Change, Sustainability, and Biotechnology (Synthetic Communities) (NSF) NSF 22-607	The goal of this solicitation is to support research that addresses one or more of the three themes: 1) define the underlying mechanisms or rules that drive the formation, maintenance or evolution of synthetic microbial communities, 2) use synthetic microbial communities to address fundamental biological questions, including questions in molecular biology, cellular/organismal biology, ecology and evolution and/or 3) build synthetic communities with biotechnology, bio-economy or environmental engineering applications. https://www.nsf.gov/pubs/2022/nsf22607/nsf22607.htm	Dependent upon proposal and available funding	Proposal: 10/3/22 8/1/24
		TOXICOLOGY (1)		
124.	New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed) (NIH/NIEHS) RFA-ES-22-006	This FOA aims to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing. Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-22-006.html	Up to \$275,766, for up to 1 year (Phase I) Up to \$1,838,436, for up to 2 years (Phase II)	Letter of intent: 10/8/22 Proposal: 11/8/22
		US AIR FORCE ACADEMY (1)		
125.	Research Interests of the United States Air Force Academy (DoD/Air Force) USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		US ARMY COMBAT CAPABILITIES DEVELOPMENT COMMAND (1)		
126.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD/Army) W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		US ARMY RESEARCH INSTITUTE (2)		
127.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD/Army) W911NF-18-S-0005	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462	Dependent upon proposal	Proposals accepted on a rolling basis until 4/29/23 Full proposal required
128.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic Scientific Research, Foundational Science Research Unit (2021-2022) (DoD/Army) W911NF-21-S-0007	The U.S. Army Research Institute for the Behavioral and Social Sciences is the Army's lead agency for the conduct of research, development, and analyses for the improvement of Army readiness and performance via research advances and applications of the behavioral and social sciences that address personnel, organization, training, and leader development issues. Programs funded under this BAA include basic research that can improve human performance and Army readiness. https://www.grants.gov/web/grants/view-opportunity.html?oppId=331391	Dependent upon proposal	White papers accepted until: 5/15/22 Proposals accepted until: 8/4/22
		US MILITARY ACADEMY (1)		
129.	United States Military Academy Broad Agency Announcement (DoD/USMA) W911NF-20-S-0008	This BAA identifies topics of interest to USMA departments, directorates, and research centers and institutes. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies. https://www.grants.gov/web/grants/view-opportunity.html?oppId=325932	Dependent upon proposal	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		US NAVY (3)		
130.	FY22 Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement (DoD/Navy) N00421-22-S-0001	NAWCAD has identified the research needed to address the challenges, problems, and future technology needs of the Warfighter. Research Opportunity Areas of Interest: AI/ML; Data Science & Visualization; Cyber; Quantum; Hypersonic Systems; Test and Evaluation Engineering; Avionics, Sensors & Electronic Warfare; Readiness & Sustainment; Materials & Aircraft Structures; Aeromechanics; Human Systems; Support Equipment; and Systems Engineering. https://sam.gov/opp/daa2293493bd43f69bf1ad9b716f7bb5/view	Dependent upon proposal	White papers accepted on a rolling basis until 6/1/23
131.	Broad Agency Announcement for Innovative Environmental Technologies and Methodologies (DoD/Navy) N3943022S2401	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/31a0cb3fe2fc4777b2f723ebe37a7d59/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 3/21/23
132.	C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research, Cryogenics & Quantum (DoD/Navy) N66001-22-S-4703	Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. https://sam.gov/opp/751823f9f7724854b4bcoc6bo8c4c857/view	Dependent upon proposal	White papers accepted on a rolling basis until: 6/7/23
		USAMRDC EXTRAMURAL BAA (1)		
133.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD/USAMRDC) W81XWH18SBAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational; Clinical and Rehabilitative Medicine; Medical Biological Defense; Medical Chemical Defense; Medical Simulation and Information Sciences Research Program. https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/22 Full proposal by invitation
		USSOCOM EXTRAMURAL R&D (1)		
134.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD/USAMRAA) W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754	Dependent upon proposal	Proposals accepted through 7/31/23 Submission of a pre-proposal is required



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		VISION HEALTH (4)		
135.	FY22 Vision Investigator- Initiated Research Award (IIRA) Clinical Trial Award (CTA) Focused Translational Team Science Award (FTTSA) Translational Research Award (TRA) (DoD/CDMRP) W81XWH-22-VRP-IIRA W81XWH-22-VRP-CTA W81XWH-22-VRP-FTTSA W81XWH-22-VRP-TRA	Applications submitted to the FY22 VRP must address one or more of the following Focus Areas: <ul style="list-style-type: none"> • Eye injury or visual dysfunction as related to military exposure. Examples of military exposure may include, but are not limited to: <ul style="list-style-type: none"> ○ Blast, penetrating, blunt, thermal, or chemical trauma ○ Directed energy weapons such as laser, high-power microwaves, particle beams and ionizing radiation • Diagnosis, stabilization, and treatment of eye injuries in austere environments and prolonged field care settings • Restoration of visual function after military exposure-related vision loss or severe visual impairment. https://cdmrp.army.mil/funding/vrp	Up to \$4 million, for up to 4 years Dependent upon award mechanism	Pre-application: 7/15/22 Proposal: 11/9/22
		WARFIGHTER MEDICAL OPTIMIZATION DIVISION (1)		
136.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD/Air Force) FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppld=327332	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26

